- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01937884
Supplemental Parenteral Nutrition in Pediatric Respiratory Failure (SuPPeR)
Optimal delivery of nutritional support during critical illness is central to appropriate intensive care unit management, and yet fundamental gaps in knowledge exist regarding timing, route, dose, and type of nutritional support for critically ill infants and children. Understanding how to optimize nutritional support during pediatric critical illness is important because even brief periods of malnutrition in infancy result in permanent negative effects on long-term neurocognitive development. Optimized nutrition support is a way to improve morbidity for survivors of pediatric critical illness. Parenteral nutrition (PN) supplementation could improve long-term neurocognitive outcome for pediatric critical illness by preventing acute malnutrition, but has unknown effects on intestinal barrier function; a proposed mechanism for late sepsis and infectious complications during critical illness.
While randomized controlled trials (RCT) support early PN in premature infants and late PN in critically ill adults, the optimal time to begin PN is unknown for critically ill infants and children. Acute malnutrition may develop within 48 hours of admission in critically ill infants and children, and repleted energy stores are predictive of survival. And yet, due to concerns for PN-associated infectious morbidity, current PICU standard of care is to supplement with PN only in children who fail to enterally feed, as late as 7 days into their admission. Delays in nutrition may have long-term effects on cognitive outcome in older infants and children. In premature infants, PN begun within hours of birth results in improved 18-month neurocognitive outcome without an increase in infectious complications. An RCT is needed to determine if early PN in critically ill infants and children prevents acute malnutrition and improves short and long-term outcomes of PICU hospitalization.
The central hypothesis of this proposal is that optimized early protein and calorie delivery will improve nutritional outcomes and intestinal barrier function for critically ill infants and children. The overall purpose of this study is to evaluate the efficacy and safety of early PN as a supplement to enteral nutrition to improve nutritional delivery, nutritional outcomes, and intestinal barrier function for infants and children with acute respiratory failure who are mechanically ventilated in the pediatric intensive care unit.
Study Overview
Status
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Arizona
-
Tucson, Arizona, United States, 85724-5073
- University of Arizona Medical Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Admitted to study hospital pediatric intensive care unit (PICU),
- One month to 16 years of age,
- Exhibits Acute Hypoxemic Respiratory Failure as defined as: PaO2/FiO2 ≤ 300 or SpO2/FiO2 ≤ 260, No evidence of cardiac dysfunction, Mechanically ventilated,
- Require artificial nutrition,
- Anticipate placement of central venous line within 24 hours of admission
Exclusion Criteria:
- Premature infants and neonates < 37 weeks corrected gestational age,
- Transfer patient on an established enteral or parenteral nutritional regimen,
- Known allergy to lactulose or mannitol,
- Pregnant,
- Admit BMI >30,
- Thoracic trauma, abdominal trauma, and/or active intracranial bleeding,
- Anuric renal failure, previous bowel surgery and/or short gut syndrome,
- Cannot be enterally fed within 24 hours of admission according to the admitting physician,
- On extracorporeal membrane oxygenation (ECMO),
- Expected survival <24 hours or limitations to aggressive ICU care (DNR),
- Receiving active CPR when admitted to the PICU,
- A pre-existing bronchopleural fistula,
- Previously enrolled and randomized into this protocol,
- Actively enrolled in another clinical trial which at the discretion of the PI would conflict with this study.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Early Parenteral Nutrition
Patients receive supplemental parenteral nutrition within 12 hours of enrollment.
Titrated with enteral nutrition to achieve target goal calories and protein.
|
|
Active Comparator: Late Parenteral Nutrition
Patients receive supplemental parenteral nutrition 96 hours after enrollment.
Titrated with enteral nutrition to achieve target goal calories and protein.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Modified Prognostic Inflammatory and Nutritional Index (PINI)
Time Frame: Change in PINI from day 0 to day 5
|
The change day 0 to day 5 of the modified Prognostic Inflammatory and Nutritional Index (PINI) is a quantitative method to monitor the relation between markers of nutrition and acute phase proteins.
It allows assessment of nutrition markers in the context of acute inflammation and in response to early enteral nutrition.
A higher baseline PINI score indicates higher degree of inflammation.
The modified PINI is calculated by the the ratio of (C-Reactive Protein(mg/dL) x Fibrinogen (mg/dL))/ (Transferrin (mg/dL) x Transthyretin (mg/dL)).
The average change in the modified PINI from day 0 to day 5 critically ill children receiving early enteral nutrition is a decrease by 5.3 +/- 3.2 (mean +/- standard error of the mean) (Briassoulis et.al.
Nutrition 2001).
A larger negative number for the change from day 0 to day 5 indicates a greater degree of inflammation resolution.
|
Change in PINI from day 0 to day 5
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Cumulative Percent of Daily Goal Calories Achieved
Time Frame: baseline and daily through day 7
|
Evaluate percentage of cumulative goal calories achieved through parenteral and enteral routes in both study arms until patient exits study participation.
Measure is calculated by (sum of kcal delivered over days of study participation/number of days in study).
|
baseline and daily through day 7
|
Plasma Intestinal Fatty Acid Binding Protein (I-FABP)
Time Frame: baseline and day 5
|
The percent change in plasma Intestinal Fatty Acid Binding Protein from baseline to study day 5, prior to late PN initiation
|
baseline and day 5
|
Plasma Citrulline
Time Frame: baseline and day 5
|
Evaluates absolute plasma citrulline concentration as a measure of functional enterocyte mass.
A higher citrulline concentration indicates a higher functional enterocyte mass.
Healthy children have an average citrulline concentration of 25 +/- 9 uMol/L.
Assessed on day 0 and day 5, results reported for day 0 and 5. Outcome analysis on difference between treatment groups on day 5.
|
baseline and day 5
|
Plasma Claudin 3
Time Frame: baseline through hour 96
|
As a measure of enterocyte tight junctions, calculate the percent change in plasma claudin 3 concentrations from baseline (day 0) and study day 5, prior to late PN administration.
|
baseline through hour 96
|
Gastrointestinal Permeability
Time Frame: day 5
|
Gastrointestinal permeability measured with the ratio of urinary recovery of lactulose and mannitol on day 5 of study participation.
The range of values is generally reported as 0.02 to 2.2 with a higher value indicating greater gastrointestinal permeability.
Values obtained on day 0 and day 5, day 5 reported.
|
day 5
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Participants With Hospital-Acquired Infections
Time Frame: until hospital discharge or day 28 if still hospitalized
|
Record any hospital-defined hospital acquired infections through day 28 in all study participants.
|
until hospital discharge or day 28 if still hospitalized
|
28-day Mortality
Time Frame: 28 days
|
Death of a study patient do to any cause measured up to 28 days after study enrollment.
|
28 days
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Katri V Typpo, MD, MPH, University of Arizona
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 13-0374
- 5K12HD047349-09 (U.S. NIH Grant/Contract)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Malnutrition
-
HAN University of Applied SciencesFrieslandCampina; HAS Hogeschool; Centre of Expertise Food (CoE Food); SligroCompletedMalnutrition; Protein | Protein MalnutritionNetherlands
-
International Centre for Diarrhoeal Disease Research...GlaxoSmithKline; Stanford UniversityCompletedMalnutrition | Malnutrition in Children | Child MalnutritionBangladesh
-
University of Nove de JulhoUnknownMalnutrition, ChildBrazil
-
UNICEFSave the ChildrenCompletedSevere MalnutritionCongo, The Democratic Republic of the
-
International Centre for Diarrhoeal Disease Research...UNICEFNot yet recruitingMalnutrition SevereBangladesh
-
Action Against Hunger USAUniversity of Washington; Ethiopian Public Health InstituteNot yet recruitingModerate Acute Malnutrition | Severe Acute Malnutrition
-
Academy of Nutrition and DieteticsHartford Hospital; University of New Mexico; Meals on Wheels Central TexasNot yet recruiting
-
Diego MorettiSwiss Federal Institute of Technology; Wageningen University and Research; St... and other collaboratorsCompletedMalnutrition; ProteinSwitzerland
-
International Centre for Diarrhoeal Disease Research...CompletedProtein MalnutritionBangladesh
-
Microbiome Health Research InstituteUniversity of Cape TownTerminatedModerate Acute Malnutrition | Severe Acute MalnutritionSouth Africa
Clinical Trials on Parenteral Nutrition
-
Hospital Pediátrico de SinaloaRecruitingCholestasis in NewbornMexico
-
Instituto do Cancer do Estado de São PauloUnknownCancer | Abdominal Surgery | Parenteral NutritionBrazil
-
Göteborg UniversityCompleted
-
University of ManchesterShire International GmbHCompleted
-
London North West Healthcare NHS TrustSt Mark's Hospital FoundationUnknownEnterocutaneous FistulaeUnited Kingdom
-
Lawson Health Research InstituteUnknownMalignant Hematologic NeoplasmCanada
-
Institut für Klinische Krebsforschung IKF GmbH...Terminated
-
Hebei Yanda Ludaopei HospitalNot yet recruitingNutrition Aspect of Cancer | Stem Cell Transplant Complications
-
University Hospital, LilleMinistry of Health, FranceTerminatedGastrointestinal Fistula | Enteral Nutritional SupportFrance
-
Tokyo UniversityCompletedDeglutition Disorders